Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Capital Leases (2019 - 2021)

Fulcrum Therapeutics (FULC) has disclosed Capital Leases for 3 consecutive years, with $2.6 million as the latest value for Q4 2021.

  • On a quarterly basis, Capital Leases fell 15.37% to $2.6 million in Q4 2021 year-over-year; TTM through Dec 2021 was $2.6 million, a 15.37% decrease, with the full-year FY2021 number at $2.6 million, down 15.37% from a year prior.
  • Capital Leases was $2.6 million for Q4 2021 at Fulcrum Therapeutics, down from $2.7 million in the prior quarter.
  • In the past five years, Capital Leases ranged from a high of $3.8 million in Q2 2019 to a low of $2.6 million in Q4 2021.
  • A 3-year average of $3.2 million and a median of $3.2 million in 2020 define the central range for Capital Leases.
  • Peak YoY movement for Capital Leases: fell 12.51% in 2020, then decreased 15.37% in 2021.
  • Fulcrum Therapeutics' Capital Leases stood at $3.5 million in 2019, then decreased by 13.35% to $3.1 million in 2020, then fell by 15.37% to $2.6 million in 2021.
  • Per Business Quant, the three most recent readings for FULC's Capital Leases are $2.6 million (Q4 2021), $2.7 million (Q3 2021), and $2.8 million (Q2 2021).